Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | F10 | P00742 | 1/20 | 0.45 |
| ▸ | PYGL | P06737 | 2/20 | 0.44 |
| ▸ | PYGM | P11217 | 1/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5739859 | 0.85 | L3MBTL1 (0.56) | TDP1L3MBTL1ALDH1A1SMN1; SMN2POLB | |
| SCHEMBL7125374 | 0.85 | TDP1 (0.58) | TDP1L3MBTL1ALDH1A1HPGDNPSR1 | |
| SCHEMBL1340946 | 0.85 | L3MBTL1 (0.56) | TDP1L3MBTL1ALDH1A1HPGDNPSR1 | |
| SCHEMBL10786894 | 0.83 | TDP1 (0.65) | TDP1L3MBTL1ALDH1A1HPGDNPSR1 | |
| SCHEMBL4606396 | 0.83 | ALDH1A1 (0.59) | TDP1L3MBTL1ALDH1A1SMN1; SMN2POLB | |
| SCHEMBL1340930 | 0.82 | MAPT (0.64) | TDP1L3MBTL1ALDH1A1HPGDNPSR1 | |
| SCHEMBL8076951 | 0.82 | L3MBTL1 (0.62) | TDP1L3MBTL1ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL7117023 | 0.82 | SMN1; SMN2 (0.64) | TDP1ALDH1A1SMN1; SMN2MAPTKMT2A | |
| SCHEMBL7117313 | 0.81 | ALDH1A1 (0.54) | TDP1L3MBTL1ALDH1A1HPGDNPSR1 | |
| SCHEMBL2608996 | 0.81 | TDP1 (0.63) | TDP1ALDH1A1HPGDNPSR1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030186944-A1 | Such as 4-(2-(3-dimethylaminobenzoylamino)phenoxy)phthalic acid for treatment/prevention of diabetes; for inhibiting liver glycogen phosphorylase; dietetics | KRISTIANSEN MARIT (DK) | 2003-10-02 | — | — | US | disclosed |
| US-6590118-B1 | Used in treatment of and/or prevention of diabetes, especially non-insulin dependent diabetes (Type 2 diabetes) | NOVO NORDISK A/S (DK) | 2003-07-08 | — | — | US | disclosed |
| EP-1220832-A1 | NOVEL AROMATIC COMPOUNDS | NOVO NORDISK A/S (DK) | 2002-07-10 | — | — | EP | disclosed |
| WO-2001023347-A1 | NOVEL AROMATIC COMPOUNDS | NOVO NORDISK A/S (DK) | 2001-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186944-A1 | Such as 4-(2-(3-dimethylaminobenzoylamino)phenoxy)phthalic acid for treatment/prevention of diabetes; for inhibiting liver glycogen phosphorylase; dietetics | PYGL, GYS2, PYGM | TDP1 1738/4885L3MBTL1 2231/4885ALDH1A1 901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.